CDK4 and pancreatic neoplasm: The observation that CDK4/6 inhibition may give rise to drug tolerance warrants additional studies to assess whether the timing of drug administration can ameliorate this effect of ribociclib, as has been proposed for palbociclib in pancreatic cancer [56].